Form 4: Revolution Medicines GC Sells Shares Under 10b5-1 Plans

Revolution Medicines' General Counsel, Jeff Cislini, reported sales of common stock totaling 2,958 shares under pre-arranged 10b5-1 plans.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc., reported two transactions involving the sale of common stock.
• On March 17, 2026, Cislini disposed of 1,795 shares of common stock at a price of $99.4804 per share.
• This transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• On March 19, 2026, Cislini disposed of an additional 1,163 shares of common stock at a price of $97.44 per share.
• This second transaction was made pursuant to a separate 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
• Following these reported transactions, Cislini beneficially owns 58,518 shares of common stock, which includes 48,125 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were pre-scheduled under 10b5-1 plans, indicating routine financial management rather than a change in the insider's outlook on the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for executives to manage personal finances, diversify holdings, and cover tax obligations without being accused of trading on material non-public information. These pre-scheduled sales are generally not interpreted as a negative signal regarding the company's future prospects, unlike unscheduled, open-market sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-scheduled sales by an insider, not indicative of company performance or a significant change in ownership structure.

Key Dates

Recommendation

The filing details routine insider stock sales executed under pre-arranged 10b5-1 plans, which are not indicative of a change in the company's fundamental value or the insider's long-term outlook. Therefore, it provides no new information to warrant a change in investment posture, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Sale, Jeff Cislini, General Counsel, 10b5-1 Plan, Restricted Stock Units, RSU